In the News

Human Hookworm Vaccine Initiative featured in Case Studies for Global Health

December 10, 2009

Sabin Vaccine’s Human Hookworm Vaccine Initiative (HHVI) is one of 32 projects chosen for inclusion in Case Studies for Global Health released on November 20, 2009 by the Alliance for Case Studies for Global Health. The Alliance is a collaboration of The Bill & Melinda Gates Foundation, World Health Organization's Special Programme for Research and Training in Tropical Diseases (TDR), Global Health Progress (GHP), International AIDS Vaccine Initiative (IAVI) and Association of University Technology Managers (AUTM).

This widely respected publication features case studies addressing a global health concern, i.e. related to diseases that have a disproportionate impact on developing countries, and is intended to educate organizations or individuals who are currently involved or are interested in helping to fulfill global health objectives.

The Human Hookworm Vaccine Initiative (HHVI), an international product development partnership based at the Sabin Vaccine Institute, was established in 2000 to develop the world’s first-ever safe, affordable, multivalent recombinant vaccine against human hookworm infection. Such a vaccine could impact an estimated 3.2 billion individuals at risk for hookworm infection.

“Human Hookworm Vaccine Initiative Designs Rapid Deployment Strategy for Developing World” details a variety of best practices and challenges in developing the hookworm infection vaccine including product design, development and manufacture, distribution, financing, intellectual property and knowledge dissemination.

The individual case study is available here while the full publication can be read here.